Virtual Insights into Natural Compounds as Potential 5α-Reductase Type II Inhibitors: A Structure-Based Screening and Molecular Dynamics Simulation Study
- PMID: 38004292
- PMCID: PMC10671996
- DOI: 10.3390/life13112152
Virtual Insights into Natural Compounds as Potential 5α-Reductase Type II Inhibitors: A Structure-Based Screening and Molecular Dynamics Simulation Study
Abstract
Androgenic alopecia (AGA) is a dermatological disease with psychosocial consequences for those who experience hair loss. AGA is linked to an increase in androgen levels caused by an excess of dihydrotestosterone in blood capillaries produced from testosterone by 5α-reductase type II (5αR2), which is expressed in scalp hair follicles; 5αR2 activity and dihydrotestosterone levels are elevated in balding scalps. The diverse health benefits of flavonoids have been widely reported in epidemiological studies, and research interest continues to increase. In this study, a virtual screening approach was used to identify compounds that interact with active site residues of 5αR2 by screening a library containing 241 flavonoid compounds. Here, we report two potent flavonoid compounds, eriocitrin and silymarin, that interacted strongly with 5αR2, with binding energies of -12.1 and -11.7 kcal/mol, respectively, which were more significant than those of the control, finasteride (-11.2 kcal/mol). Molecular dynamic simulations (200 ns) were used to optimize the interactions between compounds and 5αR2 and revealed that the interaction of eriocitrin and silymarin with 5αR2 was stable. The study shows that eriocitrin and silymarin provide developmental bases for novel 5αR2 inhibitors for the management of AGA.
Keywords: 5α-reductase type II; androgen; androgenic alopecia; dihydrotestosterone; natural compounds.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Finasteride, a Type 2 5alpha-reductase inhibitor, in the treatment of men with androgenetic alopecia.Expert Opin Investig Drugs. 1999 Apr;8(4):403-15. doi: 10.1517/13543784.8.4.403. Expert Opin Investig Drugs. 1999. PMID: 15992088
-
In silico screening of effective inhibitor of 5α-reductase type 1 for androgenic alopecia treatment.Nat Prod Res. 2022 Nov;36(22):5852-5857. doi: 10.1080/14786419.2021.2019728. Epub 2021 Dec 23. Nat Prod Res. 2022. PMID: 34937445
-
Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment.Future Med Chem. 2023 Dec;15(23):2149-2163. doi: 10.4155/fmc-2023-0065. Epub 2023 Nov 13. Future Med Chem. 2023. PMID: 37955117
-
Potential targets in the discovery of new hair growth promoters for androgenic alopecia.Expert Opin Ther Targets. 2014 Jul;18(7):787-806. doi: 10.1517/14728222.2014.922956. Epub 2014 May 30. Expert Opin Ther Targets. 2014. PMID: 24873677 Review.
-
Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.Adv Exp Med Biol. 2017;1043:473-526. doi: 10.1007/978-3-319-70178-3_22. Adv Exp Med Biol. 2017. PMID: 29224108 Review.
Cited by
-
Therapeutic Effects of Natural Products on Human Diseases.Life (Basel). 2024 Sep 14;14(9):1166. doi: 10.3390/life14091166. Life (Basel). 2024. PMID: 39337949 Free PMC article.
References
-
- Sultan C., Lumbroso S., Poujol N., Boudon C., Georget V., Terouanne B., Belon C., Lobaccaro J.M. Genetics and endocrinology of male sex differentiation: Application to molecular study of male pseudohermaphroditism. C. R. Seances Soc. Biol. Fil. 1995;189:713–740. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous